Cargando…

Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy

INTRODUCTION: Monocytes from patients with diabetes mellitus type 2 (DM2) are dysfunctional, persistently primed, and prone to a proinflammatory phenotype. This may alter the phenotype of their differentiation to macrophages and result in diabetic peripheral neuropathy (DPN), nerve damage, nerve sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado-Vázquez, Perla Abigail, Grosick, Rachel L, Moracho-Vilrriales, Carolina, Ward, Eileen, Threatt, Tiffaney, Romero-Sandoval, Edgar Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305162/
https://www.ncbi.nlm.nih.gov/pubmed/30588081
http://dx.doi.org/10.2147/JPR.S186372
_version_ 1783382503844741120
author Alvarado-Vázquez, Perla Abigail
Grosick, Rachel L
Moracho-Vilrriales, Carolina
Ward, Eileen
Threatt, Tiffaney
Romero-Sandoval, Edgar Alfonso
author_facet Alvarado-Vázquez, Perla Abigail
Grosick, Rachel L
Moracho-Vilrriales, Carolina
Ward, Eileen
Threatt, Tiffaney
Romero-Sandoval, Edgar Alfonso
author_sort Alvarado-Vázquez, Perla Abigail
collection PubMed
description INTRODUCTION: Monocytes from patients with diabetes mellitus type 2 (DM2) are dysfunctional, persistently primed, and prone to a proinflammatory phenotype. This may alter the phenotype of their differentiation to macrophages and result in diabetic peripheral neuropathy (DPN), nerve damage, nerve sensitization, and chronic pain. We have previously demonstrated that CD163 is a molecule that promotes an anti-inflammatory cellular phenotype in human primary macrophages, but this has not been proven in macrophages from patients with DM2 or DPN. Thus, we hypothesize that macrophages from patients with DM2 or DPN display an altered proinflammatory functional phenotype related to cytokine production and that the induction of CD163 expression will promote a more homeostatic phenotype by reducing their proinflammatory responsiveness. PATIENTS AND METHODS: We tested these hypotheses in vitro using blood monocyte-derived macrophages from healthy subjects and patients with DM2 with and without DPN. Cells were incubated in the presence or the absence of 5 µg/mL of lipopolysaccharide (LPS). The concentrations of interleukin-10, interleukin-6, tumor necrosis factor-alpha (TNF-α), TGF-β, and monocyte chemoattractant protein-1 (MCP-1) were measured using ELISA assays. Macrophages were transfected with an empty vector plasmid or a plasmid containing the CD163 gene using mannosylated polyethylenimine nanoparticles. RESULTS: Our results show that nonstimulated DM2 or DPN macrophages have a constitutive primed proinflammatory state and display a deficient production of proinflammatory cytokines upon a proinflammatory challenge when compared to healthy macrophages. CD163 induction produced an anti-inflammatory phenotype in the healthy control group, and this effect was partial in DM2 or DPN macrophages. CONCLUSION: Our results suggest that diabetic macrophages adopt a complex phenotype that is only partially reversed by CD163 induction. Future experiments are focused on elucidating this differential responsiveness between healthy and diabetic macrophages.
format Online
Article
Text
id pubmed-6305162
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63051622018-12-26 Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy Alvarado-Vázquez, Perla Abigail Grosick, Rachel L Moracho-Vilrriales, Carolina Ward, Eileen Threatt, Tiffaney Romero-Sandoval, Edgar Alfonso J Pain Res Original Research INTRODUCTION: Monocytes from patients with diabetes mellitus type 2 (DM2) are dysfunctional, persistently primed, and prone to a proinflammatory phenotype. This may alter the phenotype of their differentiation to macrophages and result in diabetic peripheral neuropathy (DPN), nerve damage, nerve sensitization, and chronic pain. We have previously demonstrated that CD163 is a molecule that promotes an anti-inflammatory cellular phenotype in human primary macrophages, but this has not been proven in macrophages from patients with DM2 or DPN. Thus, we hypothesize that macrophages from patients with DM2 or DPN display an altered proinflammatory functional phenotype related to cytokine production and that the induction of CD163 expression will promote a more homeostatic phenotype by reducing their proinflammatory responsiveness. PATIENTS AND METHODS: We tested these hypotheses in vitro using blood monocyte-derived macrophages from healthy subjects and patients with DM2 with and without DPN. Cells were incubated in the presence or the absence of 5 µg/mL of lipopolysaccharide (LPS). The concentrations of interleukin-10, interleukin-6, tumor necrosis factor-alpha (TNF-α), TGF-β, and monocyte chemoattractant protein-1 (MCP-1) were measured using ELISA assays. Macrophages were transfected with an empty vector plasmid or a plasmid containing the CD163 gene using mannosylated polyethylenimine nanoparticles. RESULTS: Our results show that nonstimulated DM2 or DPN macrophages have a constitutive primed proinflammatory state and display a deficient production of proinflammatory cytokines upon a proinflammatory challenge when compared to healthy macrophages. CD163 induction produced an anti-inflammatory phenotype in the healthy control group, and this effect was partial in DM2 or DPN macrophages. CONCLUSION: Our results suggest that diabetic macrophages adopt a complex phenotype that is only partially reversed by CD163 induction. Future experiments are focused on elucidating this differential responsiveness between healthy and diabetic macrophages. Dove Medical Press 2018-12-19 /pmc/articles/PMC6305162/ /pubmed/30588081 http://dx.doi.org/10.2147/JPR.S186372 Text en © 2019 Alvarado-Vázquez et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Alvarado-Vázquez, Perla Abigail
Grosick, Rachel L
Moracho-Vilrriales, Carolina
Ward, Eileen
Threatt, Tiffaney
Romero-Sandoval, Edgar Alfonso
Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title_full Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title_fullStr Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title_full_unstemmed Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title_short Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
title_sort cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305162/
https://www.ncbi.nlm.nih.gov/pubmed/30588081
http://dx.doi.org/10.2147/JPR.S186372
work_keys_str_mv AT alvaradovazquezperlaabigail cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy
AT grosickrachell cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy
AT morachovilrrialescarolina cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy
AT wardeileen cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy
AT threatttiffaney cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy
AT romerosandovaledgaralfonso cytokineproductioncapabilitiesofhumanprimarymonocytederivedmacrophagesfrompatientswithdiabetesmellitustype2withandwithoutdiabeticperipheralneuropathy